Ischemic heart disease (IHD) remains a major cause of global morbidity and mortality, with limited regenerative capacity of the adult myocardium posing a persistent therapeutic challenge. Stem cell-based interventions have emerged as a promising approach, offering the potential to restore cardiac function through angiogenesis, anti-fibrotic modulation, and tissue integration. This review comprehensively examines the therapeutic potential of three major cell types—induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), mesenchymal stem cells (MSCs), and cardiac progenitor cells (CPCs)—in both preclinical and clinical settings. iPSC-CMs demonstrate direct cardiomyocyte replacement and promote neovascularization via the VEGF/PI3K/Akt pathway. MSCs act primarily through paracrine signaling, attenuating fibrosis and inflammation via TGF-β/Smad2/3 activation, while CPCs support myocardial survival and integration through Notch signaling. Clinical trials highlight moderate improvements in left ventricular function and quality of life, particularly with MSC and CPC therapies. However, challenges persist, including cell immaturity, immune rejection, limited engraftment, and inconsistent long-term efficacy. Future directions emphasize strategies to enhance cell maturation, reduce immunogenicity, and refine clinical trial design. Integration of bioengineering techniques, gene modification, and personalized therapeutic platforms may ultimately enable the safe and effective translation of stem cell therapies into routine care for patients with IHD.

The rapid advancement of artificial intelligence (AI) in healthcare has significantly enhanced diagnostic accuracy and clinical decision-making processes. This review examines four pivotal studies that highlight the integration of large language models (LLMs) and multimodal systems in medical diagnostics. BioBERT demonstrates the efficacy of domain-specific pretraining on biomedical texts, improving performance in tasks such as named entity recognition, relation extraction, and question answering. Med-PaLM, a large-scale language model tailored for clinical question answering, leverages instruction prompt tuning to enhance accuracy and reduce harmful outputs, validated through the MultiMedQA benchmark. DR.KNOWS integrates medical knowledge graphs with LLMs, enhancing diagnostic reasoning and interpretability by grounding model predictions in structured medical knowledge. Medical Multimodal Foundation Models (MMFMs) combine textual and imaging data to improve tasks like segmentation, lesion detection, and automated report generation. These studies demonstrate the importance of domain adaptation, structured knowledge integration, and multimodal data fusion in developing robust and interpretable AI-driven diagnostic tools.

This paper explores the advancements and applications of large‐scale models in the medical field, with a particular focus on Medical Large Models (MedLMs). These models, encompassing Large Language Models (LLMs), Vision Models, 3D Large Models, and Multimodal Models, are revolutionizing healthcare by enhancing disease prediction, diagnostic assistance, personalized treatment planning, and drug discovery. The integration of graph neural networks in medical knowledge graphs and drug discovery highlights the potential of Large Graph Models (LGMs) in understanding complex biomedical relationships. The study also emphasizes the transformative role of Vision‐Language Models (VLMs) and 3D Large Models in medical image analysis, anatomical modeling, and prosthetic design. Despite the challenges, these technologies are setting new benchmarks in medical innovation, improving diagnostic accuracy, and paving the way for personalized healthcare solutions. This paper aims to provide a comprehensive overview of the current state and future directions of large models in medicine, underscoring their significance in advancing global health.

In recent years, immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of renal cell carcinoma (RCC), significantly enhanced patient outcomes and expanded therapeutic options beyond traditional surgical and targeted approaches. In this review, we provide a comprehensive review of the current applications of ICI in RCC therapy, elucidating their mechanisms of action, clinical efficacy across both clear cell and non-clear cell subtypes, and safety profiles. We compare the effectiveness of monotherapy versus combination therapies, demonstrating how synergistic approaches can improve efficacy and durability of responses. Furthermore, we explore the integration of multi-omics technologies, such as single-cell RNA sequencing and spatial transcriptomics, which are pivotal in predicting ICI response and addressing resistance mechanisms. Our discussion also addresses the critical challenges in RCC immunotherapy, including primary and acquired resistance, economic and ethical barriers, and the management of immune-related adverse events. By synthesizing current research and clinical findings, this review aims to provide valuable insights for optimizing RCC immunotherapy, fostering the development of more effective and individualized treatment protocols, and ultimately improving patient survival and quality of life.